- Home
- XERS
as 05-09-2025 4:00pm EST
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 628.7M | IPO Year: | 2018 |
| Target Price: | $6.25 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.72 - $6.07 | Next Earning Date: | 05-08-2025 |
| Revenue: | $222,551,000 | Revenue Growth: | 29.88% |
| Revenue Growth (this year): | 31.75% | Revenue Growth (next year): | 21.09% |
Stock Insider Trading Activity of Xeris Biopharma Holdings Inc. (XERS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hecht Beth | XERS | See Remarks | Mar 20 '25 | Sell | $5.43 | 40,000 | $217,244.00 | 1,353,510 |
Latest Xeris Biopharma Holdings Inc. News
XERS Breaking Stock News: Dive into XERS Ticker-Specific Updates for Smart Investing
GuruFocus.com
15 hours ago
Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...
Zacks
a day ago
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
a day ago
Xeris Biopharma: Q1 Earnings Snapshot
Business Wire
a day ago
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
Business Wire
8 days ago
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
Simply Wall St.
13 days ago
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
Insider Monkey
17 days ago
Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?
GlobeNewswire
22 days ago
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
Compare XERS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XERS Xeris Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.